Tissue-specific changes in mRNA expression of Abc and Slc transporters in murine pulmonary tuberculosis

References

• Abba K, Sudarsanam T, Grobler L, Volmink J. (2008). Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 4:CD006086.
   Google Scholar
• Alrefai WA, Gill RK. (2007). Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24(10):1803–23.
   PubMedGoogle Scholar
• Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. (2008). Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 97(9):3483–93.
   PubMedGoogle Scholar
• Athanassakis I, Mouratidou M, Sakka P, Evangeliou A, Spilioti M, Vassiliadis S. (2001). L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 1(9–10):1813–22.
   PubMedGoogle Scholar
• Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H, Inagaki N. (2007). ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem 282(13):9628–34.
   PubMedGoogle Scholar
• Basaraba RJ. (2008). Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis 88(1):S35–47.
   Google Scholar
• Berg S, Sappington P, Guzik L, Delude R, Fink M. (2003). Proinflammatory cytokines increase the rate of glycolysis and adenosine-5′-triphosphate turnover in cultured rat enterocytes. Crit Care Med 31(4):1203–12.
   PubMedGoogle Scholar
• Bottasso O, Bay M, Besedovsky H, del Rey A. (2007). The immuno-endocrine component in the pathogenesis of tuberculosis. Scand J Immunol 66(2–3):166–75.
   PubMedGoogle Scholar
• Chackerian A, Alt J, Perera T, Dascher C, Behar S. (2002). Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70(8):4501–9.
   PubMedGoogle Scholar
• Chen M, Divangahi M, Gan H, Shin D, Hong S, Lee D, Serhan C, Behar S, Remold H. (2008). Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205(12):2791–801.
   PubMedGoogle Scholar
• Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL. (2008). Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 5(1):77–91.
   PubMedGoogle Scholar
• Chimote G, Banerjee R. (2005). Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity. Colloids Surf B Biointerfaces 45(3–4):215–23.
   PubMedGoogle Scholar
• Chimote G, Banerjee R. (2008). Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis. Respir Physiol Neurobiol 162(1):73–9.
   PubMedGoogle Scholar
• Deeley RG, Westlake C, Cole SP. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86(3):849–99.
   PubMedGoogle Scholar
• Dresser MJ, Leabman MK, Giacomini KM. (2001). Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90(4):397–421.
   PubMedGoogle Scholar
• Fitzgerald ML, Xavier R, Haley KJ, Welti R, Goss JL, Brown CE, Zhuang DZ, Bell SA, Lu N, McKee M, Seed B, Freeman MW. (2007). ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res 48(3):621–32.
   PubMedGoogle Scholar
• Gabler NK, Radcliffe JS, Spencer JD, Webel DM, Spurlock ME. (2009). Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK. J Nutr Biochem 20(1):17–25.
   PubMedGoogle Scholar
• Garay SM. (1996). Pulmonary tuberculosis. In: Rom WN, Garay SM, editors. Tuberculosis. New York, NY: Little Brown. p. 373–441.
   Google Scholar
• Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38(7–8):778–801.
   Google Scholar
• Hernández-Pando R, Orozcoe H, Sampieri A, Pavón L, Velasquillo C, Larriva-Sahd J, Alcocer J, Madrid M. (1996). Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89(1):26–33.
   PubMedGoogle Scholar
• Hofmann AF, Hagey LR. (2008). Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65(16):2461–83.
   PubMedGoogle Scholar
• Jirillo E, Altamura M, Marcuccio C, Tortorella C, De Simone C, Antonaci S. (1993). Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration. Mediators Inflamm 2(7):S17–20.
   Google Scholar
• Jozefowski S, Sobota A, Kwiatkowska K. (2008). How Mycobacterium tuberculosis subverts host immune responses. Bioessays 30(10):943–54.
   PubMedGoogle Scholar
• Kashino S, Pollock N, Napolitano D, Rodrigues VJ, Campos-Neto A. (2008). Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol 153(1):56–62.
   PubMedGoogle Scholar
• Kaufmann S, Cole S, Mizrahi V, Rubin E, Nathan C. (2005). Mycobacterium tuberculosis and the host response. J Exp Med 201(11):1693–7.
   PubMedGoogle Scholar
• Kaufmann SH. (2003). Immune response to tuberculosis: experimental animal models. Tuberculosis 83(1–3):107–11.
   PubMedGoogle Scholar
• Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24(7):1227–51.
   PubMedGoogle Scholar
• Lammert F, Wang D, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey M. (2004). Spontaneous cholecysto- and hepatolithiasis in Mdr2–/– mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39(1):117–28.
   PubMedGoogle Scholar
• Lenaerts AJ, Degroote MA, Orme IM. (2008). Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 16(2):48–54.
   PubMedGoogle Scholar
• Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, Sartorelli AC. (2008). Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol 73(1):243–51.
   PubMedGoogle Scholar
• Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. (2007). Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 27(5):1004–13.
   PubMed Web of Science ®Google Scholar
• Martens GW, Arikan MC, Lee J, Ren F, Vallerskog T, Kornfeld H. (2008). Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 76(8):3464–72.
   PubMedGoogle Scholar
• Mogues T, Goodrich M, Ryan L, LaCourse R, North R. (2001). The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 193(3):271–80.
   PubMedGoogle Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer: Drug Metab Dispos. 36(2):205–16.
   PubMedGoogle Scholar
• Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD. (2006). Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60(5):1109–22.
   PubMedGoogle Scholar
• Nathan C, Gold B, Lin G, Stegman M, de Carvalho L, Vandal O, Venugopal A, Bryk R. (2008). A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis (Edinb) 88 (Suppl. 1):S25–33.
   Google Scholar
• North RJ, Jung YJ. (2004). Immunity to tuberculosis. Annu Rev Immunol 22:599–623.
   PubMed Web of Science ®Google Scholar
• Nunn A, Phillips P, Gillespie S. (2008). Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 88 (Suppl. 1):S85–92.
   PubMedGoogle Scholar
• Oude Elferink RP, Paulusma CC. (2007). Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 453(5):601–10.
   PubMedGoogle Scholar
• Palmieri O, Latiano A, Valvano R, D’Incà R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, Bossa F, Zagaria C, Andriulli A, Devoto M, Annese V. (2006). Variants of OCTN1-2 cation transporter genes are associated with both Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 23(4):497–506.
   PubMedGoogle Scholar
• Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. (2008). SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 38(7–8):972–94.
   PubMedGoogle Scholar
• Peres C, de Paula L, Medeiros A, Sorgi C, Soares E, Carlos D, Peters-Golden M, Silva C, Faccioli L. (2007). Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 9(4):483–9.
   PubMedGoogle Scholar
• Pérez-Guzmán C, Vargas M, Quiñonez F, Bazavilvazo N, Aguilar A. (2005). A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 127(2):643–51.
   PubMedGoogle Scholar
• Pinheiro VG, Ramos LM, Monteiro HS, Barroso EC, Bushen OY, Facanha MC, Peloquin CA, Guerrant RL, Lima AA. (2006). Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis 10(6):374–9.
   PubMedGoogle Scholar
• Rangel Moreno J, Estrada García I, De La Luz García Hernández M, Aguilar Leon D, Marquez R, Hernández Pando R. (2002). The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106(2):257–66.
   PubMedGoogle Scholar
• Rius M, Hummel-Eisenbeiss J, Keppler D. (2008). ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J Pharmacol Exp Ther 324(1):86–94.
   PubMedGoogle Scholar
• Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24(3):450–70.
   PubMedGoogle Scholar
• Rozen S, Skaletsky HJ. 2000. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana. p. 365–86.
   Google Scholar
• Russel FG, Koenderink JB, Masereeuw R. (2008). Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29(4):200–7.
   PubMedGoogle Scholar
• Sacks L, Behrman R. (2008). Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 88 (Suppl. 1):S93–100.
   Google Scholar
• Shekhawat PS, Srinivas SR, Matern D, Bennett MJ, Boriack R, George V, Xu H, Prasad PD, Roon P, Ganapathy V. (2007). Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(−/−)) mice. Mol Genet Metab 92(4):315–24.
   PubMedGoogle Scholar
• Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27(5):425–46.
   PubMed Web of Science ®Google Scholar
• Towler MC, Hardie DG. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100(3):328–41.
   PubMed Web of Science ®Google Scholar
• Tsuji A. (2006). Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. J Infect Chemother 12(5):241–50.
   PubMedGoogle Scholar
• Van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. (2007). Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81(3):414–9.
   PubMedGoogle Scholar
• Voshol PJ, Havinga R, Wolters H, Ottenhoff R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. (1998). Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 114(5):1024–34.
   PubMedGoogle Scholar
• Weber SS, Ragaz C, Hilbi H. (2009). Pathogen trafficking pathways and host phosphoinositide metabolism. Mol Microbiol 4:4.
   Google Scholar
• Zaher H, zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA. (2008). Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74(2):320–9.
   PubMedGoogle Scholar